Comparing sleep quality between two HIV medications
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study compares two HIV medications to see how they affect sleep quality and overall well-being in people with HIV. If you're on a dolutegravir-based regimen, you might be switched to a newer medication (doravirine) for comparison. Participation involves an overnight sleep study to monitor your sleep.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 40 years old.
- You must be HIV positive with an undetectable viral load (below 50 copies/mL).
- You must be on the same HIV medication for at least 6 months (a combination pill containing dolutegravir, TDF, and 3TC).
- You must not have a history of HIV treatment failure.
- You must have a body mass index (BMI) below 35 and weigh more than 35 kg.
- You must be willing to stay overnight in a sleep lab for a sleep study (polysomnography).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
This study tests whether switching to a new HIV medication combination (doravirine/islatravir) can improve markers of aging in people with well-controlled HIV. If you join, you would either stay on your current HIV medicines or switch to the new combination, and the study will compare how your body's aging markers change.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.